NBI-98854

Positive PhIII leaves Neurocrine lining up for an FDA filing for tardive dyskinesia
Fierce Biotech
Thu, 10/8/15 - 09:32 am
Neurocrine
FDA
NBI-98854
tardive dyskinesia
Neurocrine To Move Tardive Dyskinesia Drug Into Phase 3
Yahoo/Zacks.com
Fri, 08/8/14 - 05:55 pm
tardive dyskinesia
Neurocrine Biosciences
NBI-98854
earnings
Neurocrine Biosciences shares surge on study
Marketwatch
Mon, 01/6/14 - 04:58 pm
tardive dyskinesia
Neurocrine Biosciences
NBI-98854
Neurocrine And ChemoCentryx: Phase II Data Disappoints
Seeking Alpha
Wed, 09/11/13 - 11:25 am
Neurocrine
ChemoCentryx
CCX140
NBI-98854
tardive dyskinesia
diabetic nephropathy
Why We Think Neurocrine's Phase IIb Trial Of NBI-98854 Will Be A Success
Seeking Alpha
Sat, 07/27/13 - 11:19 am
Neurocrine Biosciences
NBI-98854
tardive dyskinesia
Neurocrine's VMAT-2 Enters Phase IIb
Seeking Alpha
Wed, 10/3/12 - 10:52 am
Neurocrine
Abbott Labs
tardive dyskinesia
NBI-98854
VMAT-2 inhibitor
Healthcare Business Review: GenVec’s Conference Success, Neurocrine Begins Trials
Wall St. Cheat Sheet
Tue, 10/2/12 - 10:30 am
GenVec
Neurocrine
NBI-98854
Neurocrine's News Not As Bad As The Market Thinks
Seeking Alpha
Wed, 03/28/12 - 10:20 am
Neurocrine
Abbott Laboratories
NBI-98854
tardive dyskinesia